Cytosorbents (NASDAQ:CTSO) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Cytosorbents Corporation's stock price has crossed above its 200-day moving average, trading at $1.08 with a volume of 51,271 shares.
• Several analysts have recently rated the stock: Wall Street Zen issued a "hold" rating, while D. Boral Capital maintains a more optimistic "buy" rating with a price target of $10.00.
• The company reported a quarterly earnings per share of ($0.05), exceeding analysts' expectations, but also noted negative metrics such as a 25.58% net margin.

Cytosorbents Corporation (NASDAQ:CTSO - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.03 and traded as high as $1.10. Cytosorbents shares last traded at $1.08, with a volume of 51,271 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CTSO. Wall Street Zen began coverage on Cytosorbents in a report on Wednesday, May 21st. They set a "hold" rating on the stock. HC Wainwright reaffirmed a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a report on Thursday, May 15th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price target on shares of Cytosorbents in a report on Friday, August 8th.

Cytosorbents Stock Up 1.9%

The company has a quick ratio of 2.30, a current ratio of 2.34 and a debt-to-equity ratio of 1.24. The firm has a market cap of $67.78 million, a price-to-earnings ratio of -6.35 and a beta of 1.19. The stock's 50 day moving average is $1.06 and its 200 day moving average is $1.03.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. The business had revenue of $9.62 million for the quarter, compared to analyst estimates of $9.79 million. Analysts forecast that Cytosorbents Corporation will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Avenir Corp increased its stake in shares of Cytosorbents by 63.1% during the first quarter. Avenir Corp now owns 5,044,918 shares of the medical research company's stock valued at $5,045,000 after acquiring an additional 1,950,972 shares during the period. Skylands Capital LLC boosted its holdings in Cytosorbents by 7.9% during the first quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock worth $3,003,000 after buying an additional 221,080 shares in the last quarter. CM Management LLC boosted its holdings in Cytosorbents by 36.3% during the first quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock worth $954,000 after buying an additional 254,076 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Cytosorbents during the fourth quarter worth approximately $99,000. Finally, Northern Trust Corp boosted its holdings in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.